Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04665856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Study acronym: SKYSCRAPER-02C
StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Study completion date changed from estimate of Jun 30, 2026 to Nov 17, 2025 · Eligibility criteria expanded, about 40 words · Secondary endpoints: 18 to 21 · 1 more Show 4 more changesShow less
    • Study completion date changed from estimate of Jun 30, 2026 to Nov 17, 2025
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: 18 to 21
    • Primary endpoints revised (2)
  2. Re-verified, no change to tracked fieldsv37
  3. Results first posted: Oct 29, 2025 Secondary endpoints: details revised at 3 of 18 entriesv36 Show 1 more changeShow less
    • Secondary endpoints: details revised at 3 of 18 entries
  4. Secondary endpoints: 16 to 18v35 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv34
Show 32 earlier versionsHide 32 earlier versions
  1. Completion date: Dec 30, 2025 to Jun 30, 2026v33
  2. Completion date: Apr 15, 2025 to Dec 30, 2025 Start date: Dec 22, 2020 to Dec 21, 2020 · Study sites revised (16)v32 Show 2 more changesShow less
    • Start date: Dec 22, 2020 to Dec 21, 2020
    • Study sites revised (16)

    See this version in full on ClinicalTrials.gov ↗

  3. 7 versions Re-verified since Sep 28, 2023, no change to tracked fieldsv25-v31
  4. Primary completion date: Jul 31, 2023 to Aug 31, 2023v24
  5. Primary completion date: Apr 27, 2023 to Jul 31, 2023v23
  6. Primary endpoints revised (2) Secondary endpoints: 17 to 16v22 Show 1 more changeShow less
    • Secondary endpoints: 17 to 16

    See this version in full on ClinicalTrials.gov ↗

  7. 2 versions Re-verified since Aug 15, 2022, no change to tracked fieldsv20-v21
  8. Primary completion date: Jun 28, 2022 to Apr 27, 2023v19
  9. Enrollment target: estimated 120 to confirmed 123v18
  10. Re-verified, no change to tracked fieldsv17
  11. Trial status: Recruiting to Active, Not Recruiting Site details revised at 16 of 16 sitesv16 Show 1 more changeShow less
    • Site details revised at 16 of 16 sites
  12. Trial status: Active, Not Recruiting to Recruiting Site details revised at 16 of 16 sitesv15 Show 1 more changeShow less
    • Site details revised at 16 of 16 sites
  13. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 128 to confirmed 120 · Site details revised at 16 of 16 sitesv14 Show 2 more changesShow less
    • Enrollment target: estimated 128 to confirmed 120
    • Site details revised at 16 of 16 sites
  14. Trial status: Active, Not Recruiting to Recruiting Site details revised at 16 of 16 sitesv13 Show 1 more changeShow less
    • Site details revised at 16 of 16 sites
  15. Re-verified, no change to tracked fieldsv12
  16. Trial status: Recruiting to Active, Not Recruiting Site details revised at 16 of 16 sitesv11 Show 1 more changeShow less
    • Site details revised at 16 of 16 sites
  17. Site details revised at 2 of 16 sitesv10
  18. Study sites: 17 to 16v9
  19. Study sites: 18 to 17v8
  20. Site details revised at 1 of 18 sitesv7
  21. Primary endpoints revised (2) Enrollment target: 108 to 128 · Eligibility criteria expanded, about 49 words · Secondary endpoints: 10 to 17 · 1 morev6 Show 4 more changesShow less
    • Enrollment target: 108 to 128
    • Eligibility criteria expanded, about 49 words
    • Secondary endpoints: 10 to 17
    • Site details revised at 2 of 18 sites

    See this version in full on ClinicalTrials.gov ↗

  22. Study sites: 14 to 18v5
  23. Site details revised at 1 of 14 sitesv4
  24. Site details revised at 3 of 14 sitesv3
  25. Start date changed from estimate of Jan 4, 2021 to Dec 22, 2020 Study title shortened, about 1 wordv2 Show 1 more changeShow less
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Trial Details
NCT Number NCT04665856
Lead Sponsor Hoffmann-La Roche
Conditions Small Cell Lung Carcinoma
Enrollment 123 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov